{To Share} STOMP_TA2_Literature_Landscape.xlsx

	A	B	C
1	STOMP TA2 Literature Landscape — Read me first
2	ARPA-H-SOL-26-152 · 111-study literature landscape with editorial flags on team claims
3
4	Quick orientation
5	This workbook is a structured literature landscape for the STOMP TA2 solution summary, covering 111 studies on MNP toxicology + nanoparticle/ultrafine PM parallels. It supports three tasks: (1) finding the right citations for each section of the summary; (2) understanding which existing studies inform each of the team's 8 capability areas; (3) flagging where team members' SOTA-baseline claims are outdated, oversold, or directly refuted by recent literature, so they can be revised before submission.
6
7	What is in each tab
8
9	Tab	What it contains	Best used for
10	1. Read me first	This tab. Onboarding for new collaborators.	Navigation.
11	2. Literature Master	All 111 studies, one row each. Columns: ID, citation, journal, DOI, PMID, year, study type, particle type, size, route, dose, key finding, limitations, why it matters for STOMP TA2, capability tags (one cell per capability), TA2-tight-scope flag, nanoparticle-parallel flag, preprint flag, matters-arising/correction notes, category. Frozen panes; auto-filter on; TA2-tight-scope rows shaded light green; nanoparticle-parallel rows shaded pale yellow.	Day-to-day citation work.
12	3. By capability	Pivoted view: one column per team capability area, rows organized by study category. Cells contain study IDs that bear on that capability. Quickly find: 'which studies inform Yao's PA/US claims?' or 'which studies should Chatterjee cite for hierarchical Bayesian PK?'	Section-by-section drafting.
13	4. Team claim vs literature	9 editorial flags where a team member's SOTA-baseline claim is contradicted, weakened, or oversold by the literature. Each row: team member, claim, status, primary evidence, supporting study IDs, blunt assessment, suggested action, priority. High-priority items shaded orange.	Pre-submission revision triage.
14	5. Citation reliability	14 caveats: preprints, active 'Matters Arising' disputes (Nihart, Marfella), Author Corrections, DOIs requiring verification, team-cited PMIDs that may not match the intended paper, and a no-retractions-found note.	Final-submission citation hygiene.
15
16
17	Top-line findings (from the literature review)
18
19	Well established: MNPs detected in essentially every human tissue/fluid examined (blood, brain, liver, placenta, lung, atherosclerotic plaque, heart, vein, testis, colon, stool, tumor tissues including cervical cancer). PS-NP exposure in rodents reproducibly causes oxidative stress, inflammation, mitochondrial dysfunction, and behavior changes. Cardiovascular signal (Marfella 2024 HR 4.5×) and BBB-crossing signal are robust. Contested or weak: Inter-laboratory measurement variation is severe (BAM 2025 ILC: 62-129% S_R). Almost all human MNP-disease associations remain correlational. Most rodent studies use unrealistic doses and pristine PS spheres rather than weathered/mixed environmental MNPs (Djouina 2026 is the key exception). Aging-stratified MNP work exists but is sparse (Gaspar 2023, Bailey 2025). No published study has performed true longitudinal multi-modal whole-body imaging of MNPs in living rodents during chronic environmental exposure — this is the team's strongest defensible whitespace. Whitespace for STOMP TA2: quantitative dosimetric multi-modal imaging (Yao PA/US + Guo PET co-registered) + aging-stratified multi-omics (Stolzing + Ginkgo) on weathered, environmentally-realistic MNP mixtures (per Djouina 2026 protocol). None of those three modifiers is well-covered in the existing literature.
20
21	Color coding (used across all tabs)
22
23	TA2 tight scope	Light green - study informs one of our 8 team capability areas directly.
24	Nanoparticle parallel	Pale yellow - foundational nanoparticle/ultrafine PM precedent.
25	High-priority conflict	Darker peach - team claim that will fail peer review unless revised.
26	Matters arising / correction	Peach - paper has active critique, correction, or contamination dispute.
27
28
29	What's inside (counts)
30
31	Total studies	111
32	TA2 tight scope (informs ≥1 team capability)	92
33	Nanoparticle / ultrafine PM parallels	17
34	Preprints (use with appropriate framing)	5
35	Studies with active matters arising / corrections	6
36	Editorial conflicts flagged	9
37	High-priority conflicts (revise before submission)	3
38	Citation reliability items	14
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100